SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESOPRNewsWire • 08/29/23
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in ChildrenGlobeNewsWire • 08/04/23
Are You Looking for a Top Momentum Pick? Why Mesoblast Limited (MESO) is a Great ChoiceZacks Investment Research • 06/23/23
Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023GlobeNewsWire • 05/25/23
FDA Accepts Mesoblast's Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023GlobeNewsWire • 03/08/23
Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022GlobeNewsWire • 02/27/23
DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)GlobeNewsWire • 02/27/23
Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and TherapyGlobeNewsWire • 02/16/23
FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back PainGlobeNewsWire • 02/08/23
Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)GlobeNewsWire • 01/31/23
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing FacilityGlobeNewsWire • 12/23/22
Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 12/15/22